Nasaruplase beta (USAN/INN);
Prolyse (TN)

C2031H3121N585O601S31

46313.2981

46343.16

SNELHQVPSN CDCLNGGTCV SNKYFSNIHW CNCPKKFGGQ HCEIDKSKTC YEGNGHFYRG
KASTDTMGRP CLPWNSATVL QQTYHAHRSD ALQLGLGKHN YCRNPDNRRR PWCYVQVGLK
PLVQECMVHD CADGKKPSSP PEELKFQCGQ KTLRPRFKII GGEFTTIENQ PWFAAIYRRH
RGGSVTYVCG GSLISPCWVI SATHCFIDYP KKEDYIVYLG RSRLNSNTQG EMKFEVENLI
LHKDYSADTL AHHNDIALLK IRSKEGRCAQ PSRTIQTICL PSMYNDPQFG TSCEITGFGK
ENSTDYLYPE QLKMTVVKLI SHRECQQPHY YGSEVTTKML CAADPQWKTD SCQGDSGGPL
VCSLQGRMTL TGIVSWGRGC ALKDKPGVYT RVSHFLPWIR SHTKEENGLA L
(Disulfide bridge: 11-19, 13-31, 33-42, 50-131, 71-113, 102-126, 148-279, 189-205, 197-268, 293-362, 325-341, 352-380; Glycosylation site: 18, 302)

Fibrinolytic, Thrombolytic, Stroke treatment, Urokinase plasminogen activator (u-PA)

urokinase plasminogen activator (u-PA) [HSA:5328] [KO:K01348] [EC:3.4.21.73]
Treatment of acute ischemic stroke